Kolexia
Fischbach Cathie Médecine générale
Fischbach Cathie
Médecine générale
Centre Paul Strauss
Strasbourg, France
37 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Carcinome épidermoïde Fatigue Carcinomes COVID-19 Carcinome épidermoïde de la tête et du cou Tumeurs du côlon Cachexie Carcinome pulmonaire non à petites cellules

Collaborateurs

Voir plus
Kalish Michal
Kalish Michal
Centre Paul Strauss, Strasbourg, France
Petit Thierry
Petit Thierry
Centre Paul Strauss, Strasbourg, France
Pierard Laure
Pierard Laure
Hôpital Hautepierre, Strasbourg, France
Pivot Xavier
Pivot Xavier
Centre Paul Strauss, Strasbourg, France

Industries

Voir plus
A+A
6 collaboration(s)
Dernière en 2021
Mylan Medical
5 collaboration(s)
Dernière en 2021
MSD
2 collaboration(s)
Dernière en 2021
B3TSI
2 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Anaplastic Lymphoma Kinase Inhibitor-Induced Neutropenia: A Systematic Review.
Cancers   11 octobre 2023
Capecitabine efficacy after cycline-dependent-kinase 4/6 inhibitor plus endocrine therapy in metastatic hormone receptor-positive breast cancer.
Cancer treatment and research communications   25 juin 2023
A propensity score-weighted study comparing a two- versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer.
Breast cancer research and treatment   23 décembre 2022
Consequences of Discontinuing a 4/6 Cyclin D-Dependent Kinase Inhibitor During Endocrine Treatment in Hormone-Sensitive Metastatic Breast Cancer Patients in the Context of the COVID-19 Outbreak.
Clinical breast cancer   13 octobre 2022
Abstract P1-17-07: Consequences of stopping a 4/6 cyclin D-dependent kinase Inhibitor in metastatic breast cancer patients with clinical benefit on endocrine treatment, in the context of the COVID-19 outbreak
2021 San Antonio Breast Cancer Symposium   15 février 2022
Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients.
Frontiers in oncology   27 octobre 2021
286P Outcome of patients with HER2-positive brain metastatic breast cancer: A 10-year retrospective study
Abstract Book of the ESMO Congress 2021, 16 – 21 September 2021   01 septembre 2021
319P A propensity score weighted study comparing two versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer
Abstract Book of the ESMO Congress 2021, 16 – 21 September 2021   01 septembre 2021
Persistent taxane-induced neuropathy in elderly patients treated for localized breast cancer.
The breast journal   11 décembre 2020
930P Weekly paclitaxel, carboplatin and cetuximab (PCC) as first-line treatment of recurrent and/or metastatic head & neck squamous cell carcinoma (R/M-HNSCC) for patients ineligible to cisplatin based chemotherapy
Abstract Book of the ESMO Virtual Congress2020 19 – 21 September / 16 – 18 October 2020   01 septembre 2020